aTYR PHARMA INC Finance Lease, Principal Payments
aTYR PHARMA INC (ATYR) reported Finance Lease, Principal Payments of $287.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Financing Activities
us-gaap:FinanceLeasePrincipalPayments · last filed 2026-08-07
- aTYR PHARMA INC finance lease, principal payments for the quarter ending 2026-06-30 was $145.00K, a 9.02% increase year-over-year.
- aTYR PHARMA INC finance lease, principal payments for the quarter ending 2026-03-31 was $142.00K, a 8.40% increase year-over-year.
- aTYR PHARMA INC finance lease, principal payments for the quarter ending 2025-12-31 was $139.00K, a 8.59% increase year-over-year.
- aTYR PHARMA INC finance lease, principal payments for the quarter ending 2025-09-30 was $136.00K, a 8.80% increase year-over-year.
- aTYR PHARMA INC finance lease, principal payments for fiscal 2025 was $539.00K, a 8.45% increase from fiscal 2024.
- aTYR PHARMA INC finance lease, principal payments for fiscal 2024 was $497.00K, a 26.14% increase from fiscal 2023.
- aTYR PHARMA INC finance lease, principal payments for fiscal 2023 was $394.00K, a 496.97% increase from fiscal 2022.
- aTYR PHARMA INC finance lease, principal payments for fiscal 2022 was $66.00K.
| Period end | Finance Lease, Principal Payments 3 month | Finance Lease, Principal Payments 6 month | Finance Lease, Principal Payments 9 month | Finance Lease, Principal Payments 9 month as first filed | Finance Lease, Principal Payments 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $145.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $287.00K 10-Q · filed 2026-08-07 | $426.00K derived: sum of 3 quarters · filed 2026-08-07 | $562.00K derived: sum of 4 quarters · filed 2026-08-07 | |
| 2026-03-31 | $142.00K 10-Q · filed 2026-05-15 | $281.00K derived: sum of 2 quarters · filed 2026-05-15 | $417.00K derived: sum of 3 quarters · filed 2026-05-15 | $550.00K derived: sum of 4 quarters · filed 2026-08-07 | |
| 2025-12-31 | $139.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $275.00K derived: sum of 2 quarters · filed 2026-03-05 | $408.00K derived: sum of 3 quarters · filed 2026-08-07 | $539.00K 10-K · filed 2026-03-05 | |
| 2025-09-30 | $136.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $269.00K derived: sum of 2 quarters · filed 2026-08-07 | $400.00K 10-Q · filed 2025-11-06 | $528.00K derived: sum of 4 quarters · filed 2026-08-07 | |
| 2025-06-30 | $133.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-07 | $264.00K 10-Q · filed 2026-08-07 | $392.00K derived: sum of 3 quarters · filed 2026-08-07 | $517.00K derived: sum of 4 quarters · filed 2026-08-07 | |
| 2025-03-31 | $131.00K 10-Q · filed 2026-05-15 | $259.00K derived: sum of 2 quarters · filed 2026-05-15 | $384.00K derived: sum of 3 quarters · filed 2026-05-15 | $507.00K derived: sum of 4 quarters · filed 2026-05-15 | |
| 2024-12-31 | $128.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $253.00K derived: sum of 2 quarters · filed 2026-03-05 | $376.00K derived: sum of 3 quarters · filed 2026-03-05 | $497.00K 10-K · filed 2026-03-05 | |
| 2024-09-30 | $125.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $248.00K derived: sum of 2 quarters · filed 2025-11-06 | $369.00K 10-Q · filed 2025-11-06 | $484.00K derived: sum of 4 quarters · filed 2026-03-05 | |
| 2024-06-30 | $123.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $244.00K 10-Q · filed 2025-08-07 | $359.00K derived: sum of 3 quarters · filed 2026-03-05 | $467.00K derived: sum of 4 quarters · filed 2026-03-05 | |
| 2024-03-31 | $121.00K 10-Q · filed 2025-05-07 | $236.00K derived: sum of 2 quarters · filed 2026-03-05 | $344.00K derived: sum of 3 quarters · filed 2026-03-05 | $449.00K derived: sum of 4 quarters · filed 2026-03-05 | |
| 2023-12-31 | $115.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $223.00K derived: sum of 2 quarters · filed 2026-03-05 | $328.00K derived: sum of 3 quarters · filed 2026-03-05 | $394.00K 10-K · filed 2026-03-05 | |
| 2023-09-30 | $108.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $213.00K derived: sum of 2 quarters · filed 2024-11-07 | $279.00K 10-Q · filed 2024-11-07 | $345.00K derived: sum of 4 quarters · filed 2025-03-13 | |
| 2023-06-30 | $105.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $171.00K 10-Q · filed 2024-08-13 | $237.00K derived: sum of 3 quarters · filed 2025-03-13 | $237.00K derived: sum of 4 quarters · filed 2025-03-13 | |
| 2023-03-31 | $66.00K 10-Q · filed 2024-05-02 | $132.00K derived: sum of 2 quarters · filed 2025-03-13 | $132.00K derived: sum of 3 quarters · filed 2025-03-13 | $132.00K derived: sum of 4 quarters · filed 2025-03-13 | |
| 2022-12-31 | $66.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $66.00K derived: sum of 2 quarters · filed 2025-03-13 | $66.00K derived: sum of 3 quarters · filed 2025-03-13 | $66.00K 10-K · filed 2025-03-13 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | $24.00K 10-Q · filed 2022-11-14 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $0.00 10-Q · filed 2023-08-09 | |||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-09 | ||||
| 2021-12-31 | $0.00 10-K · filed 2024-03-14 | ||||
| 2020-12-31 | $0.00 10-K · filed 2023-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |